JYMed Peptide

Peptide CDMO founded 2009 with R&D HQ in Shenzhen and API plant in Hubei. 10 cGMP lines, 30,000L SPPS/LPPS reactor volume, current output 4+ tons/year expanding to 10+ tons by 2027. 27 commercial peptide APIs with active DMFs. FDA, ICH, EDQM, and NMPA inspection history.

JYMed Peptide is listed as a CDMO in the peptide supply chain, serving Asia markets from China (Shenzhen). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 3 independent sources, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.